Site search
Bibliography
Cannabinoids and cardiovascular disease: the outlook for clinical treatments
Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. john.ashton@stonebow.otago.ac.nz
Cannabinoid drugs exert their effects primarily through activation of cannabinoid CB1 and CB2 receptors. Both...
Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: Insulin and melanocortins
Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli (NA), Italy.
Endocannabinoids are paracrine/autocrine lipid mediators with several...
What do we know about obesity?
Medicina Interna, Dipartimento di Medicina e Scienze dell'Invecchiamento, Facoltà di Medicina e Chirurgia, Università G. D'Annunzio, Chieti-Pescara, Italia. guagnano@unich.it
The prevalence of obesity is increasing rapidly in...
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data
Division of General Internal Medicine, Department of Medicine, University of Nevada School of Medicine, Reno, NV 89557, USA. kbronander@medicine.nevada.edu
The endocannabinoid system (ECS) is an endogenous physiological system...
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group
Obesity Research Center, St Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025,...
Displaying results 11 to 15 out of 15
This section of the site is dedicated to published Rimonabant related scientific studies that discuss its use and effects.